The estimated Net Worth of Anthony Pare is at least $90.4 Thousand dollars as of 17 March 2021. Mr. Pare owns over 9,620 units of T2 Biosystems Inc stock worth over $72,708 and over the last 17 years he sold TTOO stock worth over $17,701. In addition, he makes $0 as Chief Commercial Officer at T2 Biosystems Inc.
Sign up
Mr. Pare TTOO stock SEC Form 4 insiders trading
Anthony has made over 5 trades of the T2 Biosystems Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he sold 9,620 units of TTOO stock worth $17,701 on 17 March 2021.
The largest trade he's ever made was exercising 17,500 units of T2 Biosystems Inc stock on 14 March 2021 worth over $40,250. On average, Anthony trades about 4,050 units every 673 days since 2008. As of 17 March 2021 he still owns at least 31,612 units of T2 Biosystems Inc stock.
You can see the complete history of Mr. Pare stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Anthony Pare biography
Anthony Pare serves as Chief Commercial Officer of the Company. Mr. Pare joined our company in April 2019 as Vice President and General Manager of International, Prior to joining T2. Mr. Pare was the Chief Commercial Officer for Hemanext, a pre-revenue company developing a new technology that improves the quality, consistency and efficacy of red cell transfusion therapy from July 2016 to April 2019. Prior to joining Hemanext. Mr. Pare was the Vice President of Business Development. Mergers and Acquisitions for Haemonetics Corporation, a blood management company from January 1997 to May 2015. Mr. Pare received a B.S. in Engineering from Maine Maritime Academy and a Masters in Engineering Administration from George Washington University.
How old is Anthony Pare?
Anthony Pare is 58, he's been the Chief Commercial Officer of T2 Biosystems Inc since 2020. There are 8 older and 9 younger executives at T2 Biosystems Inc. The oldest executive at T2 Biosystems Inc is John Cumming, 74, who is the Lead Independent Director.
What's Anthony Pare's mailing address?
Anthony's mailing address filed with the SEC is 101, Hartwell Avenue, Lexington, Middlesex County, Massachusetts, 02421, United States.
Insiders trading at T2 Biosystems Inc
Over the last 10 years, insiders at T2 Biosystems Inc have traded over $18,971,153 worth of T2 Biosystems Inc stock and bought 5,875,341 units worth $59,722,018 . The most active insiders traders include Adrian M Jones, Group L.P.Crg Partners Iii ..., and Thomas J. Carella. On average, T2 Biosystems Inc executives and independent directors trade stock every 20 days with the average trade being worth of $764,499. The most recent stock trade was executed by John J Iii Sperzel on 24 February 2024, trading 67 units of TTOO stock currently worth $154.
What does T2 Biosystems Inc do?
t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www
What does T2 Biosystems Inc's logo look like?
Complete history of Mr. Pare stock trades at T2 Biosystems Inc and Haemonetics
T2 Biosystems Inc executives and stock owners
T2 Biosystems Inc executives and other stock owners filed with the SEC include:
-
John McDonough,
Non-Executive Chairman of the Board -
Alec Barclay,
Chief Operating Officer -
John J. Sperzel III, B.Sc.,
Chairman & CEO -
Thomas Lowery,
Chief Scientific Officer -
Alec J. Barclay,
Chief Operations Officer -
Seymour Liebman,
Director -
David Elsbree,
Independent Director -
John Cumming,
Lead Independent Director -
Philip Taylor,
IR Contact Officer -
Robin Toft,
Independent Director -
Ninfa Saunders,
Independent Director -
Thierry Bernard,
Independent Director -
Anthony Pare,
Chief Commercial Officer -
Michael Gibbs,
Vice President, General Counsel -
John Sprague,
Chief Financial Officer -
John Sperzel,
President, Chief Executive Officer, Director -
Brett A. Giffin,
Chief Commercial Officer -
Dr. Aparna Jha Ahuja M.D.,
Chief Medical Officer -
Kelley J. Morgan,
Chief People Officer -
Michael Terrence Gibbs,
VP & Gen. Counsel -
John M. Sprague CPA,
Chief Financial Officer -
Aparna Ahuja,
Chief Medical Officer -
Brett A. Giffin,
Chief Commercial Officer -
Joanne Spadoro,
Chief Operations Officer -
Stanley Lapidus,
Director -
Rahul Dhanda,
SVP of Corporate Development -
Sachs Group Incgoldman Sach...,
-
Shawn Lynch,
Chief Financial Officer -
Joshua H. Bilenker,
Director -
David Harding,
Chief Commercial Officer -
Michael J. Cima,
Director -
Harry W Wilcox,
Director -
Group L.P.Crg Partners Iii ...,
-
Darlene M Deptula Hicks,
Chief Financial Officer -
Stanley N Lapidus,
Director -
Thomas J. Carella,
-
Michael A. Pfaller,
Chief Medical Officer -
Venture Partners V, L.P.Pol...,
-
Sarah O. Kalil,
Chief Operating Officer -
Maurice L Castonguay,
Chief Financial Officer -
Advisors, L.L.C. Mbd,
-
Venture Partners V, L.P.Pol...,
-
Sachs Group Incgoldman Sach...,
-
Alan L Crane,
Director -
Ventures Fund 2004 L P Flag...,
-
Capital Iii Lp Aisling Capi...,
-
Laura Lee Adams,
-
Adrian M Jones,
Director -
Sachs & Co. Llcgoldman Sach...,
-
Group L.P.Crg Partners Iii ...,